About us

Sandy Mou, MD, serves as Board Executive Director and Chief Executive Officer at CORXEL. She is responsible for leading the full scope of business operations of the company.

Sandy Mou has nearly 30 years of experience in the pharmaceutical and medical device industry in China and has held management positions at several multinational pharmaceutical companies including GSK, AstraZeneca, Xi’an Janssen, Johnson & Johnson Medical and MSD. She has led teams to successfully launch several leading brands covering a wide range of therapeutic areas including cardiovascular and metabolic diseases, orthopedics, immunology and oncology. In May 2017, Sandy joined MSD China to establish the oncology business unit and oversaw several product launches including Keytruda. Under her leadership, the MSD China’s oncology business was ranked among the top three oncology businesses of multinational pharmaceutical companies in China after just three years. In March 2020, Sandy joined Shanghai Allist Pharmaceutical Technology Co. (Allist) as the Chief Executive Officer. During her tenure, Allist was successfully listed on the Science and Technology Board of the Shanghai Stock Exchange, achieved the first new drug approval, commercial launch and listing in the National Reimbursement Drug List. Under Sandy’s leadership, Allist has completed the transformation from a biotech company to an innovative biopharmaceutical company with integrated R&D, manufacturing and commercialization capabilities and has achieved profitability.

Sandy graduated from Shanghai Medical College of Fudan University with a bachelor's degree in Medicine and worked as a clinician for 7 years after graduation. Sandy also holds an EMBA degree from China Europe International Business School.  

Dr. Kevin Xie serves as the Chief Financial Officer at CORXEL, where he oversees the company's capital strategy, financial operations, and investor relations.

With over 20 years of experience in healthcare investment and operations, Kevin brings a wealth of expertise and leadership to the organization. Most recently, Kevin served as the Chief Financial Officer of Gracell Biotechnologies, beginning in July 2020. During his tenure, he played a pivotal role in several landmark achievements, including the company's crossover financing in 2020, its Nasdaq IPO in 2021, a subsequent secondary equity PIPE financing in 2023, and Gracell's eventual acquisition by AstraZeneca in 2024. In addition, Kevin also oversaw Gracell's U.S. non-clinical operations. Prior to joining Gracell, Kevin was the President of Healthcare Holdings for Fosun Group and Chief Representative of Fosun NY from 2015 to 2020. In this role, he led Fosun Group's global healthcare investment initiatives. Before Fosun, Kevin spent over a decade in senior management positions at several prominent healthcare investment firms in the United States. He co-founded Locust Walk Capital, served as Healthcare Sector Head at Scopia Capital, and was a Managing Director at Great Point Partners. In addition to his executive roles, Kevin has served on the boards of directors of multiple publicly traded companies.

Kevin holds an MBA from The Wharton School at the University of Pennsylvania and a Ph.D. in Chemistry from the City University of New York.      

Edmond Chen, MD, serves as the Chief Medical Officer at CORXEL. He is responsible for the overall development and execution of global clinical programs, advancing CORXEL’s growing assets and portfolio with the objective of gaining broad regulatory approvals and market authorizations across the world.  He is based in the United States.

Edmond is a seasoned clinical development leader in the pharmaceutical industry, with extensive international drug development experience, having worked at a diverse range of pharmaceutical companies, from small biotechnology firms to global pharmaceutical giants such as Merck and Bayer. He was most recently Senior Vice President at BioCryst, advancing their development portfolio and overseeing the clinical development/research function.  He has worked extensively across diverse therapeutic areas from rare diseases to large cardiovascular areas including congestive heart failure, thrombosis, and therapeutics for primary and secondary prevention.  Most notably, he helped advance thrombosis care with the successful approval of a first-in-class antiplatelet agent Vorapaxar for use in the secondary prevention of coronary and peripheral artery disease and the introduction of Rivaroxaban, a direct oral anticoagulant to the secondary prevention of coronary, cerebrovascular, and peripheral artery disease.

Edmond earned his MD (Doctorate in Medicine) from the University of California, San Francisco, where he also completed training in internal medicine and cardiology.  Prior to joining industry, he practiced at the Kaiser Permanente and served as the Chief of Cardiology.  He is a Fellow of the American College of Cardiology. He completed his undergraduate studies at the University of California, Berkeley.

Dr. Bo Liang, MD, serves as the Senior Vice President, Head of Clinical Development – Metabolic, at CORXEL. Bo is responsible for the overall development strategy, the execution of clinical trials and the registration of innovative metabolic programs. He is based in Denmark.

Before joining CORXEL, Bo was the Senior Vice President of Clinical Development (Metabolic Therapy Area) at Hengrui Pharmaceuticals. In this role, he was responsible for global development strategies and execution in the fields of diabetes, obesity, MASH (Metabolic Associated Steatohepatitis), and other metabolic related areas. Prior to this, he served as the Senior Director and Acting Vice President at Novo Nordisk A/S, where he was responsible for therapeutic area strategies and execution in the diabetes field. He led and participated in the global clinical development and regulatory submissions of innovative treatments such as Icodec (the first once weekly insulin formulation), Semaglutide (once weekly GLP-1 RA), and the IcoSema fixed-dose combination.  

Bo graduated with a Medical Doctor (MD) degree from Tongji University and eared his PhD at the Faculty of Health Science at the University of Copenhagen in Denmark. He was appointed as an Associate Professor at the University of Copenhagen in 2013, where he enagaed in research on the pathogenesis of arrhythmias and the development of new drugs.

Rainy (Yucong) Zhou serves as Senior Vice President, Regulatory Affairs at CORXEL. Rainy is responsible to lead all of CORXEL's Regulatory Affair activities and communications with regulatory agencies, as well as the design of the clinical development and registration strategy for each of CORXEL's assets in China.

Rainy has more than 20 years of industry experience in Regulatory Affairs at Multinational Pharmaceutical Companies across several therapeutic areas. Before joining JIXING, Rainy worked at Novartis for seven years as Director Regulatory Affairs, overseeing the therapeutic areas of Immunology, Hepatology, Dermatology and Transplant, and contributing to the development of Novartis’ regulatory strategy for a pipeline of new products. She led the team through the successful submission and approvals of several CTAs and NDAs, meanwhile maintaining marketed products. Prior to joining Novartis, Rainy worked at Sanofi, Eli Lily and Bayer, covering numerous therapeutic areas including Cardiovascular, CNS, Women’s Health and Diabetes. Rainy has also been strongly involved in shaping the policy ecosystem in the past years in China.

Rainy holds a master’s degree in Clinical Medicine from Nankai University.

Christine Dai serves as Chief Human Resources Officer of CORXEL. In this role, Christine will lead the HR team and collaborate with CORXEL's Leadership Team to define and develop the strategic direction and key approaches for organization & talents’ development. She will also refine, land and evolve the differentiated corporate culture of CORXEL, for the sustainable growth of organization, business and talents.

Before joining CORXEL, Christine worked as HR Head of Speiyou in TAL Education which is a fast-growing top K12 Education Group with more than 30K employees in China from May 2020 till October 2021. Before that she held the role of HR VP/ HR General Manager in Fosun Pharma responsible for the overall HR management of Fosun Pharma HQ and membership enterprises with more than 20K employees worldwide. Prior to Fosun, she worked at Novartis for more than 16 years, and served in diverse roles with increasing responsibilities, including HR Manager of Shared Service Center, HRBP Head of Specialty BUs, HR Head of GCPO Beijing (Greater China Pharma Organization-North China), HR Head of OTC Greater China & South Korea, HR Head of NBS (Novartis Business Services) Greater China, and Head of TAS (Talent Acquisition & Staffing) Greater China. Before Novartis, Christine started her career at China International Intellectech Co. Ltd. (CIIC), a SOE HR outsourcing & consulting services’ provider, as business representative.

Christine received her bachelor’s degree in English literature from China University of Political Science and Law and a BiMBA diploma from Novartis-Beijing University BiMBA program, as well as a diploma from Novartis-IMD Emerging Leadership Program.  

Lisa Tian serves as Senior Vice President, Head of Finance at CORXEL. In this role, Lisa oversees the entire Finance function including Treasury, Tax, Accounting, Procurement, FP&A, Internal Controls and IT. Lisa reports to the CFO and is a member of Leadership Team of CORXEL. 

Before joining CORXEL, Lisa worked as Finance Head of Innocare which is a fast-growing Bio-pharma including R&D, manufacturing and commercialization from Sep 2020 till Jun 2022. During her time at Innocare, Lisa supported their post HKex Finance operations and involved in their A-listing process in STAR board. Before that she held the role of deputy CFO in Fosun Pharma-Medical device, mainly responsible for the overseas medical device finance and business operations in mainland China & HK. Prior to Fosun, she worked at Novartis & Alcon for more than 5 years, and served in diverse roles with increasing responsibilities, including Greater China FRA Head and Country Lead of SAP project. She also worked in GE Healthcare acted as GPRS Asia Finance Head, then relocated to GE Healthcare US HQ as global FP&A. Prior of GE Healthcare, Lisa served in pharmaceutical companies like Bayer Healthcare, Sanofi-Aventis etc.  

Lisa received her bachelor’s degree of Economics in The Capital of Business & Economics University, and she is an Associate Member of AAIA.

John Li serves as General Counsel & Chief Compliance Officer at CORXEL. John is responsible for leading the Legal & Compliance function to provide professional legal advice and solutions to facilitate execution of CORXEL’s business strategy. He works closely with leadership team to build a robust compliance program to further enhance CORXEL’s compliance culture.

Before joining CORXEL, John worked as General Counsel and VP of Legal & Compliance Department at Burning Rock which is a Nasdaq-listed leading diagnostic company with business presence in both China and US. Before that he was Legal Head of Nutrition BG and Legal Head of Diagnostic BG of Abbott China, a Fortune 500 healthcare company. Prior to Abbott, John worked for several leading US law firms including Latham, MOFO and Orrick, where he advised international and domestic clients on general corporate, private equity and capital market matters.

John received his bachelor’s degree and master’s degree in law from Fudan University, as well as his master’s degree in law from Columbia University in NYC. He passed China national judicial exam and was admitted to New York Bar.

Horch Guo serves as Vice President, Head of TechOps at CORXEL.  In this position, Horch leads Supply Chain, Production, Quality, Engineering and CMC functions. He is responsible for developing and implementing manufacturing strategies, procedures, organization & budget plans to strengthen the products’ portfolio with efficient technology transfer, robust local manufacturing, quick product launch and reliable supply chain.  

Horch brings rich technical operations and team management experience in pharmaceutical industry. Prior to joining JIXING, Horch was Site Head of Everest Medicines for the overall site management (Jiashan Site), and the Deputy General Manager of Luoxin Aurovitas Pharma (Chengdu) where he acted as the General Manager being responsible for the entire site operation and management, product introduction strategy, tech transfer and financial management etc. Before joining Luoxin, Horch ever worked in Edding Pharma, Roche, Bayer and Sanofi respectively with experiences of license-in, process development, technology transfer, manufacturing operations, engineering, CAPEX & investment management, Joint Venture/Company setup and operation etc. with increasing responsibilities.

Horch obtained his Bachelor’s and Master’s degree of pharmaceutics from China Pharmaceutical University and Shanghai Institute of Pharmaceutical Industry respectively. Horch also obtained his Master’s degree of Financial Management from Shanghai University of Finance and Economics.